At a glance
- Originator AstraZeneca
- Class Antiasthmatics
- Mechanism of Action Neurokinin 2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 08 Feb 2008 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 08 Feb 2008 Discontinued - Preclinical for Asthma in United Kingdom (unspecified route)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed